Tectonic Therapeutic to Attend Major Investor Conferences
Tectonic Therapeutic, Inc. (NASDAQ: TECX), a clinical-stage biotechnology company dedicated to discovering and developing therapeutic proteins and antibodies that influence G-protein coupled receptors (GPCRs), has announced that its management team will be participating in important investor events.
Wells Fargo Healthcare Conference
Tectonic will take part in the 2024 Wells Fargo Healthcare Conference, where management will have the chance to share insights about the company's progress and future strategies.
Conference Details
Date: September 4-6, 2024
Time: 3:45 PM ET
Presenter: Alise Reicin, MD, President, CEO, and Director of Tectonic Therapeutic
Format: Fireside Chat
Morgan Stanley Global Healthcare Conference
The company will also participate in the Morgan Stanley 22nd Annual Global Healthcare Conference, where they will hold one-on-one meetings with potential investors.
Conference Details
Date: September 6, 2024
Format: Investor one-on-one meetings
Live Webcast Access
Investors can tune in to a live webcast of the fireside chat from the Wells Fargo Healthcare Conference on Tectonic's website in the Investors section. A replay will be accessible for about 90 days after the event.
About Tectonic
Tectonic Therapeutic is committed to developing biologic medicines that target GPCRs, utilizing its proprietary GEODe™ technology platform. This innovative method aims to overcome challenges in drug discovery and address diseases with significant unmet medical needs. The company’s leading product candidate, TX000045 (TX45), is a distinctive Fc-relaxin fusion protein currently undergoing a Phase 2 clinical trial aimed at patients with Group 2 Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction, fulfilling a crucial need in the healthcare sector. Tectonic is dedicated to enhancing patient quality of life and increasing longevity through its groundbreaking therapies.
Company Contacts
Investors: Dan Ferry, LifeSci Advisors, daniel@lifesciadvisors.com (617) 430-7576
Media: Karen Sharma, CG Life, ksharma@cglife.com (617) 571-2733
Frequently Asked Questions
What is Tectonic Therapeutic focused on?
Tectonic Therapeutic specializes in discovering and developing therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs).
Which conferences will Tectonic attend?
Tectonic will be present at the Wells Fargo Healthcare Conference and the Morgan Stanley Annual Global Healthcare Conference.
Who is presenting at the Wells Fargo Conference?
Alise Reicin, MD, who serves as the President and CEO of Tectonic Therapeutic, will be the presenter at the Wells Fargo Conference.
What is TX000045 (TX45)?
TX000045 (TX45) is Tectonic’s leading product candidate, an Fc-relaxin fusion protein designed to treat Group 2 Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction.
How can investors access the webcast?
Investors can access the live webcast on the Tectonic website in the Investors section, and a replay will be available for 90 days following the event.